Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMLX Amylyx Pharmaceuticals

Market Closed 03-20 16:00:00 EDT

13.81

-0.24

-1.71%

盘后13.81

+0.000.00%

18:02 EDT

High14.35	Low13.69	Vol1.57M
Open14.13	D1 Closing14.05	Amplitude4.73%
Mkt Cap1.53B	Tradable Cap903.86M	Total Shares110.54M
T/O21.83M	T/O Rate2.40%	Tradable Shares65.45M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AMLX","market":"US","secType":"STK","nameCN":"Amylyx Pharmaceuticals","latestPrice":13.81,"timestamp":1774036800000,"preClose":14.05,"halted":0,"volume":1572143,"hourTrading":{"tag":"盘后","latestPrice":13.81,"preClose":13.81,"latestTime":"18:02 EDT","volume":118596,"amount":1637788.7499,"timestamp":1774044179277,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.017081850533807844,"floatShares":65449399,"shares":110536944,"eps":-1.530525,"marketStatus":"Market Closed","change":-0.24,"latestTime":"03-20 16:00:00 EDT","open":14.13,"high":14.3544,"low":13.69,"amount":21834096.491873,"amplitude":0.047288,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.530525,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1641531600000,"exchange":"NASDAQ","adjPreClose":14.05,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":14.12,"preClose":14.05,"latestTime":"09:29 EDT","volume":3440,"amount":48569.38064,"timestamp":1774013399999,"change":0.07,"changeRate":0.004982,"amplitude":0.019217},"postHourTrading":{"tag":"盘后","latestPrice":13.81,"preClose":13.81,"latestTime":"18:02 EDT","volume":118596,"amount":1637788.7499,"timestamp":1774044179277,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.518923614106545,"impliedVol":0.6099,"impliedVolPercentile":0.6335},"requestUrl":"/m/hq/s/AMLX/wiki","defaultTab":"wiki","newsList":[{"id":"2620226054","title":"Amylyx Pharmaceuticals Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2620226054","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620226054?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:00","pubTimestamp":1773928800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 10:00 ET (14:00 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"1115814310","title":"Stock Track | Amylyx Pharmaceuticals Soars 5.24% Intraday After H.C. Wainwright Raises Price Target to $34","url":"https://stock-news.laohu8.com/highlight/detail?id=1115814310","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115814310?lang=en_us&edition=fundamental","pubTime":"2026-03-05 00:30","pubTimestamp":1772641838,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals' stock soared 5.24% during intraday trading on Wednesday, following a bullish analyst update from H.C. Wainwright.The firm's analyst, Andrew Fein, raised the price target on...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AMLX"],"gpt_icon":0},{"id":"2617044554","title":"Amylyx Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2617044554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617044554?lang=en_us&edition=fundamental","pubTime":"2026-03-05 00:12","pubTimestamp":1772640720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2026 11:12 ET (16:12 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616255956","title":"Amylyx price target raised to $34 from $28 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616255956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616255956?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:38","pubTimestamp":1772635090,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Amylyx (AMLX) to $34 from $28 and keeps a Buy rating on the shares. Following...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-price-target-raised-to-34-from-28-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-price-target-raised-to-34-from-28-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616556795","title":"Amylyx Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $34 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2616556795","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616556795?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:30","pubTimestamp":1772634602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nAZN4SJJUG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"1126914858","title":"Stock Track | Amylyx Pharmaceuticals Plummets 5.52% Intraday Following Shelf Offering Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=1126914858","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126914858?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:52","pubTimestamp":1772549544,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals' stock plummeted 5.52% during intraday trading on Tuesday, following the company's announcement of a mixed securities shelf offering.The biotechnology firm filed for an...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["AMLX"],"gpt_icon":0},{"id":"2616326279","title":"Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2616326279","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616326279?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:31","pubTimestamp":1772548260,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryAmylyx Pharmaceuticals Inc AMLX.OQ reported a quarterly adjusted loss of 30 cents per share for the quart","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL8N3ZR1WK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2616203328","title":"Amylyx files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2616203328","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616203328?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:12","pubTimestamp":1772543552,"startTime":"0","endTime":"0","summary":"08:07 EST Amylyx (AMLX) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-files-automatic-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2616834077","title":"Amylyx Pharmaceuticals Inc - Files for Mixed Shelf Offering; Size Not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2616834077","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616834077?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542975,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0Q0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616347293","title":"Amylyx reports Q4 EPS (30c), consensus (34c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616347293","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616347293?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:37","pubTimestamp":1772541436,"startTime":"0","endTime":"0","summary":"“2025 was a year of meaningful advancement for Amylyx’s (AMLX) pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-reports-q4-eps-30c-consensus-34c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-reports-q4-eps-30c-consensus-34c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616427173","title":"Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2616427173","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616427173?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:13","pubTimestamp":1772540010,"startTime":"0","endTime":"0","summary":"Earnings Flash (AMLX) Amylyx Pharmaceuticals Posts Q4 Net Loss $0.30 a Share, vs. FactSet Est of $0.29 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616342904","title":"Amylyx Pharmaceuticals Q4 net loss beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342904","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342904?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:08","pubTimestamp":1772539687,"startTime":"0","endTime":"0","summary":"Amylyx Pharmaceuticals Q4 net loss beats estimatesOverviewPharmaceutical firm's Q4 loss per share beat analyst expectationsNet loss for Q4 beat analyst estimatesCompany expects cash runway to fund ope","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL1N3ZR0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616342861","title":"Amylyx posts FY 2025 net loss of USD 144.7 million, down 52.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342861","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342861?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:01","pubTimestamp":1772539268,"startTime":"0","endTime":"0","summary":"Amylyx reported a Q4 net loss of USD 33.0 million and a FY net loss of USD 144.7 million. Q4 R&D expenses were USD 21.2 million and Q4 SG&A expenses were USD 15.4 million, while FY R&D expenses were USD 90.4 million and FY SG&A expenses were USD 62.9 million. Cash, cash equivalents and short-term investments totaled USD 317.0 million at December 31, 2025, and the company said its cash runway is expected to extend into 2028. On the business side, Amylyx said recruitment is complete for its pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia , with topline data expected in Q3 2026 and, if approved, a commercial launch in 2027. The company also announced AMX0318, a novel GLP-1 receptor antagonist designed for long-acting administration, as a development candidate for PBH and other rare diseases, with IND-enabling studies underway and an IND filing targeted for 2027. In addition, Amylyx presented early Phase 1 LUMINA safety and tolerability data for AMX0114 in ALS an","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL4Qc08y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616342817","title":"Amylyx Pharma Q4 EPS $(0.30) Beats $(0.36) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342817","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342817?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539255,"startTime":"0","endTime":"0","summary":"Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.9 percent. This is a 45.45 percent increase over losses of $(0.55) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/50994721/amylyx-pharma-q4-eps-0-30-beats-0-36-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616424863","title":"Amylyx Pharmaceuticals Inc - Cash Runway Expected to Fund Operations Through Potential Avexitide Commercialization and Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2616424863","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616424863?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLX2D64A8:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2616344486","title":"Amylyx Pharmaceuticals Q4 Operating Income USD -36.605 Million VS. Ibes Estimate USD -40.4 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344486?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLX2D64A8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AMLX"],"gpt_icon":0},{"id":"2616344485","title":"Amylyx Pharmaceuticals Q4 Operating Expenses USD 36.605 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344485","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344485?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLX2D64A8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2616342154","title":"Amylyx Pharmaceuticals Inc - Phase 3 Lucidity Trial Topline Data Anticipated in Q3 2026 & Commercial Launch in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2616342154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616342154?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLX2D64A8:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMLX","BK4007"],"gpt_icon":0},{"id":"2616634253","title":"Press Release: Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2616634253","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616634253?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:00","pubTimestamp":1772539200,"startTime":"0","endTime":"0","summary":"--  Recruitment of the pivotal Phase 3 LUCIDITY trial of avexitide in PBH. is complete; continue to expect to randomize and dose last eligible. participants in Q1 2026, with topline data anticipated in Q3 2026. --  Cash runway expected to fund operations through potential avexitide. Amylyx Pharmaceuticals, Inc.   today reported financial and business results for the fourth quarter and full year ended December 31, 2025.\"2025 was a year of meaningful advancement for Amylyx's pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline,\" said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. \"In 2026, our primary focus is on our Phase 3 LUCIDITY trial of avexitide in PBH. With recruitment of LUCIDITY complete, we are on track to complete enrollment this month and continue to expect topline data in Q3 2026. We designed LUCIDITY with the goal of replicating and building on the robust body of evidence demonstrating statistically significant reducti","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASO","LU0128526141.USD","PBH","PSP","BK4561","HI","LU0029874061.USD","LU2125154778.USD","AMLX","LU2360032135.SGD","BK4007","BK4161","IND","BK4200","LU2125154935.USD"],"gpt_icon":0},{"id":"2616344783","title":"This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344783","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344783?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:57","pubTimestamp":1772539020,"startTime":"0","endTime":"0","summary":"Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all changes. AMLX, OFRM, AGMB, SGP initiated with positive outlook.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/03/Analysts-Debate-Depreciation-Impact.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/03/Analysts-Debate-Depreciation-Impact.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/50994386/this-amylyx-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-4-initiations-for-tuesday-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/26/03/50994386/this-amylyx-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note-here-are-top-4-initiations-for-tuesday-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BLSG","BK4112","BLSX","AMLX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amylyx.com","stockEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":-0.0206},{"period":"3month","weight":0.1489},{"period":"6month","weight":0.0376},{"period":"1year","weight":2.7024},{"period":"ytd","weight":0.1432}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.074034},{"month":2,"riseRate":0.6,"avgChangeRate":0.089231},{"month":3,"riseRate":0.2,"avgChangeRate":-0.325305},{"month":4,"riseRate":0.25,"avgChangeRate":-0.062706},{"month":5,"riseRate":0.25,"avgChangeRate":-0.046188},{"month":6,"riseRate":0.75,"avgChangeRate":0.347356},{"month":7,"riseRate":1,"avgChangeRate":0.206362},{"month":8,"riseRate":0.5,"avgChangeRate":0.025088},{"month":9,"riseRate":0.75,"avgChangeRate":0.218209},{"month":10,"riseRate":0.75,"avgChangeRate":0.212399},{"month":11,"riseRate":0.75,"avgChangeRate":0.011294},{"month":12,"riseRate":0.25,"avgChangeRate":-0.127185}],"exchange":"NASDAQ","name":"Amylyx Pharmaceuticals","nameEN":"Amylyx Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amylyx Pharmaceuticals,AMLX,Amylyx Pharmaceuticals股票,Amylyx Pharmaceuticals股票老虎,Amylyx Pharmaceuticals股票老虎国际,Amylyx Pharmaceuticals行情,Amylyx Pharmaceuticals股票行情,Amylyx Pharmaceuticals股价,Amylyx Pharmaceuticals股市,Amylyx Pharmaceuticals股票价格,Amylyx Pharmaceuticals股票交易,Amylyx Pharmaceuticals股票购买,Amylyx Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amylyx Pharmaceuticals(AMLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amylyx Pharmaceuticals(AMLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}